Atopic dermatitis and skin diseaseThe many routes of dendritic cells to ensure immune regulation
References (16)
- et al.
Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion
J Allergy Clin Immunol
(2009) - et al.
Tuning microenvironments: induction of regulatory T cells by dendritic cells
Immunity
(2008) - et al.
Dendritic cells: bridging innate and adaptive immunity in atopic dermatitis
J Allergy Clin Immunol
(2010) - et al.
Regulation of TH17 cells in the mucosal surfaces
J Allergy Clin Immunol
(2009) - et al.
Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells
J Allergy Clin Immunol
(2011) - et al.
Mechanisms and treatment of allergic disease in the big picture of regulatory T cells
J Allergy Clin Immunol
(2009) - et al.
Interleukin-10-secreting type 1 regulatory T cells in rodents and humans
Immunol Rev
(2006) - et al.
Oral tolerance
Immunol Rev
(2005)
Cited by (17)
Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers
2017, Journal of Allergy and Clinical ImmunologyCitation Excerpt :During subsequent allergen exposure, IgE-facilitated allergen recognition through FcεRI on DCs and FcεRII on B cells amplifies the development of TH2 responses to inhaled allergens (Fig 1, B). DCs, depending on their maturation phase, their location, and the associated local cytokine milieu, can either initiate and maintain allergic inflammation (proallergic DC2s)32,33,37,38 or alternatively promote a state of immune tolerance (tolerogenic regulatory dendritic cells [DCregs])32,33,39-42 to sensitizing allergens. DC2s express the markers CD141, GATA-3, OX40 ligand, and receptor-interacting serine/threonine-protein kinase 4 (RIPK4).33
Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens
2015, World Allergy Organization JournalCitation Excerpt :The immune system forms an interactive network with tissues and makes it’s decisions on the basis of signals coming from resident tissue cells, infectious agents, commensal bacteria and almost any environmental agents. Our research during the last years has focused on different aspects for the development of novel concepts on how the immune system tolerates allergens, and how allergic diseases should be redefined accordingly [1-29]. In recent years, induction of immune tolerance has become a prime target for prevention and treatment strategies for many diseases in which dysregulation of the immune system plays an important role [30].
Betalactam antibiotics affect human dendritic cells maturation through MAPK/NF-kB systems. Role in allergic reactions to drugs
2015, Toxicology and Applied PharmacologyCitation Excerpt :Markedly, given the different degrees of p38 MAPK activation in AX-stimulated DCs among the allergic patients and the effect of NF-kB and MAPK pharmacological inhibition on DC surface markers, we could also hypothesize that there might be different subsets of DCs that are responsible for a particular responder phenotype in AX allergic patients. This circumstance has been lately outlined from a broader perspective for allergic reactions and it could have an impact for personalized immunotherapies (Palomares et al., 2011). The fact that AX induced maturation of imDCs only in allergic patients but not in tolerant subjects might indicate that this process was initially produced in the presence of another stimulus, like TLR agonists, that acted as a danger priming signal and which did not occur in controls (Sanchez-Quintero et al., 2013).
Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood
2013, Journal of Allergy and Clinical ImmunologyImmunology of graft rejection
2013, Kidney Transplantation-Principles and Practice, Seventh EditionC-Type Lectin Receptor Mediated Modulation of T2 Immune Responses to Allergens
2023, Current Allergy and Asthma Reports
Disclosure of potential conflict of interest: L. O’Mahony is a consultant for Alimentary Health Ltd and receives research support from the Swiss National Science Fund. C. A. Akdis receives research support from Novartis, Stallergenes, the Swiss National Science Foundation, the Global Allergy and Asthma European Network, and the Christine Kühne Center for Allergy Research; is a fellow and interest group member of the American Academy of Allergy, Asthma & Immunology; is Vice President of the European Academy of Allergy and Clinical Immunology; and is an ex-committee member WP leader for GA2LEN. O. Palomares had declared that he has no conflict of interest.